Session 2: From molecular target to molecular resistance in NSCLC - Panel discussion Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Session 3: From molecular addiction to therapeutic strategy in NSCLC - Panel discussion Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Session 5: From PD1/PD-L1 monotherapy in selected patients to PD1/PD-L1 combo for all NSCLC - Panel discussion Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019
Panel discussion: Improving the pathway of lung cancer patients, can we do it better? Source: ERS webinar 2021: Panel discussion on improving the pathway of lung cancer patients, can we do it better? Year: 2021
LSC - 2020 - Comprehensive characterization of the immune landscape within different molecular subtypes of small cell lung cancer (SCLC) Source: Virtual Congress 2020 – Biological aspects of lung cancer Year: 2020
DNA methylation profiling of non-small cell lung cancer reveals an immune signature in COPD patients Source: Annual Congress 2013 –New strategies in epigenomic research to study lung diseases (DNA rearrangements, RNA, methylation, proteosome) Year: 2013
Major changes in men with non-small-cell lung cancer (NSCLC) in 10 years: The KBP-2000-CPHG and KBP-2010-CPHG cohorts Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer Year: 2013
ERS School Course Early-stage lung cancer - What's new in the epidemiology of lung cancer: the female aspect Source: ISSN=ISSN 1810-6838, ISBN=, page=339 Year: 2006
Lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement: Analysis of two cases and literature review Source: International Congress 2016 – Basic science and case reports in lung cancer Year: 2016
Significance of EGFR expression patterns in patients with non-small cell lung cancer – Evaluation on protein- and/or gene level? Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014
Biomarkers for non-small cell lung cancer (NSCLC) treatment: examples and unmet needs, a clinical perspective Source: International Congress 2014 – From bench to bedside: biomarkers and biobanking for lung cancer in 2014 Year: 2014
Differences in epidemiological and clinical features in non-small cell lung cancer (NSCLC) in never and ever smokers Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015
Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)? Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015
Role of hypoxia in epithelial-to-mesenchymal transition (EMT) in non-small cell lung cancer (NSCLC) Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014
COPD and lung cancer: Prevalence, infradiagnosis, phenotypes and multidimensional characterization Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer Year: 2016
Distribution of CD4+Foxp3+,CD4+ and CD8+ T cells in non-small cell lung cancer Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer Year: 2015
A tissue microarray analysis on the role of chromosome 7 multiplication regarding the EGFR expression in non-small cell lung carcinomas Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016